Detection of human papilloma (HPV) virus types 16,18, 31 y 33 in severe dysplasias and carcinoma-in-situ of the uterine cervix
Abstract
Introduction: severe dysplasia and carcinoma-in-situ (CIN) is actually the first grade of uterine cervical cancer. HPV infection constitutes an important etiological factor for the origin of High-grade Squamous Intraepithelial Lesion (H-SIL) and uterine cervical epidermoid cancer.
Objective: to determine the prevalence of HPV types that are described as more frequent in other regions, from a sample of Uruguayan women carriers of severe dysplasia and uterine cervix carcinoma in situ, with diagnosis confirmed by the histological study of surgical conization pieces.
Method: we selected a sample of surgical conization pieces from women who were carriers of severe dysplasia and intraepithelial epidermoid cancer of the uterine cervix in Montevideo and Canelones. Pieces were fixed in formol and then embedded in paraffin.
Results: we identified the presence of HPV deoxiribonucelic acid (DNA) in 39 out of 49 patients (80%). The most common type of virus found was HPV 16 in 23 of cones (47%), followed by HPV 33, found in seven cases (14%). We stand out the absence of HPV 18 in this sample.
Conclusion: we proved the usual association between HPV infections and precursor lesions to uterine cervical cancer. Among the four types of HPV studied and described as more common in other regions, we identified HPV 16 as the most common, the same as it happens in other parts of the world.
References
(2) National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA 1989; 262(7): 931-4.
(3) Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287(16): 2114-9.
(4) Ostor G. Natural history of cervical Intraepitelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12(2): 186-92.
(5) Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, ShahKV, et al. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9.
(6) Muñoz N, Castellsagué X, Berrington A, Gissman L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 (Suppl 3): S1-10.
(7) Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah K. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55(4): 244-65.
(8) Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89(1): 101-5.
(9) Clifford G, Franceschi S, Diaz M, Muñoz N, Villa L. Chapter 3: HPV type distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24 Suppl 3: S26-34.
(10) Cuschieri K, Cubie H, Whitley M, Gilkinson G, Arends, Graham C, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005; 58(9): 946-50.
(11) Solomon D. Role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr 2003; (31): 97-101.
(12) Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2 ed. New York: Cold Spring Harbor, 1989.
(13) De Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3’ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76 (pt 4):1057-62.
(14) Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, et al. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol 1996; 34(3): 745-47.
(15) Sanguinetti CJ, Dias Neto E, Simpson AJ. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994; 17(5): 914-21.
(16) International Agency for Research on Cancer. International Agency for Research on Cancer-Cervical cancer screening. IARC Handbooks of cancer prevention Nro. 10. Lyon: IARC, 2005.
(17) Insigna R, Liaw K, Johnson L, Madeleine M. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17(7): 1611-22.
(18) Wheeler C, Hunt W, Joste N, Key C, Quint W, Castle P. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101(7): 475-87.
(19) Sigurdson K, Taddeo F, Benediktsdottir K, Olafsdottir K, Sigvaldason H, Oddsson K, et al. HPV genotypes in CIN 2-3 lesions and cervical cancer: a population-based study. Int J Cancer 2007; 121(12): 2682-7.
(20) Smith J, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high grade cervical. Lesions: a meta-analysis update. Int J Cancer 2007; 121(3): 621-32.
(21) Koshiol J, Lindsay L, Pimenta J, Poole C, Jenkins D, Smith J. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168 (2): 123-37.
(22) Maucort-Boulch D, Franceschi S, Plummer M. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev 2008; 17(3): 717-20.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
